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SUMMARY
Hotspot mutations in splicing factor genes have been recently reported at high frequency in 
hematological malignancies, suggesting the importance of RNA splicing in cancer. We analyzed 
whole-exome sequencing data across 33 tumor types in The Cancer Genome Atlas (TCGA), and 
we identified 119 splicing factor genes with significant non-silent mutation patterns, including 
mutation over-representation, recurrent loss of function (tumor suppressor-like), or hotspot 
mutation profile (oncogene-like). Furthermore, RNA sequencing analysis revealed altered splicing 
events associated with selected splicing factor mutations. In addition, we were able to identify 
common gene pathway profiles associated with the presence of these mutations. Our analysis 
suggests that somatic alteration of genes involved in the RNA-splicing process is common in 
cancer and may represent an underappreciated hallmark of tumorigenesis.
Graphical abstract
In Brief: Seiler et al. report that 119 splicing factor genes carry putative driver mutations over 33 
tumor types in TCGA. The most common mutations appear to be mutually exclusive and are 
associated with lineage-independent altered splicing. Samples with these mutations show 
deregulation of cell-autonomous pathways and immune infiltration.
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INTRODUCTION
Alternative pre-mRNA splicing is a major source of transcript diversity in mammalian cells 
and is orchestrated by a megadalton complex called the spliceosome (Papasaikas and 
Valcárcel, 2016). The major U2-type spliceosome constitutes five small nuclear 
ribonucleoprotein (snRNP) complexes (U1, U2, U4, U5, and U6) and >150 proteins, while 
the minor U12-type spliceosome contains five snRNPs and an unknown number of proteins, 
many of which have analogous genes in the U2 spliceosome. In a dynamic process, pre-
mRNA non-coding intron sequences are removed at specific splice sites, leaving coding 
exons that are ligated to form mature mRNA. These introns and exons contain sequences 
that are recognized by the core splicing machinery and are essential for recruitment and 
activation of the splicing process. Additionally, there are cis silencer and enhancer sequences 
that are recognized by accessory factors, e.g., heterogeneous nuclear ribonucleoproteins 
(hnRNPs) and serine/arginine-rich (SR) proteins, and these factors are responsible for 
splicing regulation (Wang et al., 2008). Recurrent somatic mutations of the splicing factor 
genes SF3B1, SRSF2, U2AF1, and ZRSR2 were first discovered through whole-exome 
sequencing in myelodysplastic syndrome (MDS) (Yoshida et al., 2011), and they were later 
reported in other hematological malignancies as well as solid tumors (Makishima et al., 
2012; Papaemmanuil et al., 2013; Haferlach et al., 2014; Lindsley et al., 2015; Jeromin et 
al., 2014; Landau et al., 2015; Patnaik et al., 2013). Differential splicing analysis using RNA 
sequencing data from patient samples and pre-clinical models revealed that these somatic 
mutations induced transcriptome-wide splicing alterations (Ferreira et al., 2014; DeBoever et 
al., 2015; Darman et al., 2015; Zhang et al., 2015; Kim et al., 2015; Okeyo-Owuor et al., 
2015; Przychodzen et al., 2013; Madan et al., 2015).
The confluence of both DNA and RNA sequencing in TCGA provide a unique opportunity 
to interrogate splicing deregulation due to somatic mutation across human cancers. Although 
systematic analyses of mutations, copy number, and gene expression patterns of RNA-
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binding proteins (RBPs) have recently been reported (Sebestyén et al., 2016; Neelamraju et 
al., 2018), here we focus on somatic mutations in known splicing factors and alternative 
splicing events associated with selected mutations across 33 tumor types and more than 
10,000 samples. Furthermore, we compare how these mutations affect gene pathways in the 
affected lineages, and we examine their potential impact on tumorigenesis.
RESULTS
119 Splicing Factor Genes Carry Recurrent Mutations in Hematological Cancers and Solid 
Tumors
We compiled and curated a catalog of 404 splicing factor genes (Table S1; STAR Methods), 
and we prioritized genes with likely driver mutations using two complementary approaches 
(Figure 1A). The first approach, MutSigCV (Lawrence et al., 2013), ranks genes by 
statistical significance of somatic mutation per cohort adjusted by mutation background of 
tumor type, gene size, replication time, and gene expression levels. We identified 68 genes 
as significantly mutated in at least one cohort (q value ≤ 0.1). The second approach, a 
ratiometric method (Vogelstein et al., 2013), identifies likely oncogenes and tumor 
suppressors based on the observation that oncogenes are recurrently mutated at the same 
amino acid position (hotspot, HS), whereas tumor suppressor genes are mutated through 
loss-of-function (LoF) mutations throughout their length. Using this method, we identified 
77 genes as either likely oncogene (OG) or tumor suppressor gene (TSG) using either 
individual tumor cohorts (72 genes) or a pancan cohort of all samples (5 genes). Similar 
results were also obtained by a recently published ratio-metric method, 20/20+ (Tokheim et 
al., 2016) (Figure S1C). Among the 77 genes, 27 were also identified by MutSigCV, while 
50 were uniquely identified by this approach only. Finally, ZRSR2 was added as it has been 
previously identified in hematological tumors as significantly mutated, though it did not 
meet our driver gene criteria in TCGA. Together, we prioritized 119 genes as likely 
harboring driver mutations (Table S1).
We mapped these 119 genes to known U2 and U12 spliceosome complexes and their 
associated proteins (Figure 1B; Table S1A). Among components of the U2 spliceosome, we 
observed that driver mutations primarily impacted proteins involved in the early stages of 
splicing catalysis, from pre-catalytic (complex A) to the first catalytic step (complex C). 
Proteins associated with the U2 snRNP were especially well-represented among hotspot 
mutants, including SF3B1, U2AF1, and PHF5A. In the U12-type spliceosome, prior reports 
have described ZRSR2 LoF mutations, primarily in MDSand secondary leukemia, that are 
associated with the retention of U12 spliceosome introns (Yoshida et al., 2011; 
Papaemmanuil et al., 2013; Haferlach et al., 2014; Lindsley et al., 2015; Madan et al., 2015). 
Here we identified 3 recurrently mutated genes (SNRNP35, SNRNP48, and ZCRB1) that are 
also part of the U12 spliceosome. The recurrent hotspot mutations in SNRNP48 and ZCRB1 
in acute myeloid leukemia (LAML) indicate that U12-splicing deregulation in hematological 
malignancies are more prevalent than previously reported.
Globally, the non-silent mutation rate of individual splicing factor genes is low, ranging from 
0.16% (PHF5A) to 3.7% (SPEN) (Figure S1A; Table S1B); however, we observed a number 
of genes with exceptionally high mutation rates in otherwise infrequently mutated tumors 
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(e.g., SF3B1 in uveal melanoma [UVM] and FUBP1 in low-grade glioma [LGG]) (Figure 
S1A). Segregating LoF and hotspot mutation rates in each gene by tumor type revealed 
genes with high percentage of HS or LoF mutations across multiple tumor types (Figure 
1D), and we found that LoF mutations are much more common than hotspot mutations 
(Figure 1C). Overall, we observed a significant linear relationship between the number of 
samples with likely splicing factor driver mutations and the log10 mutation rate per sample 
in the corresponding cohort (p = 4.02e–11) (Figure S1B). Bladder carcinoma (BLCA), skin 
cutaneous melanoma (SKCM), and lung adenocarcinoma (LUAD) were most likely to 
harbor non-silent mutations in any putative driver splicing factor, at more than 60% of 
patients in each cohort. Of these tumor types, BLCA and UVM had significantly higher rates 
of splicing factor driver mutations than would be expected by chance (p = 0.01 and 0.03, 
respectively), suggesting that splicing deregulation is an important hallmark for these 
tumors.
Due to the importance of splicing factor mutations in cancer, we analyzed the transcriptomic 
consequences associated with mutations with exceptional frequency in a single cohort and 
with hotspot (SF3B1, U2AF1, and SRSF2) or LoF mutations (RBM10 and FUBP1) in 
samples that were not associated with hyper-mutator phenotypes (see the STAR Methods).
SF3B1 Hotspot Mutations Induce Aberrant Splicing
SF3B1 has been reported to be the most frequently mutated splicing factor gene in 
hematological malignancies and some solid tumors, such as adenoid cystic carcinoma 
(Martelotto et al., 2015), breast cancer (Cancer Genome Atlas Network, 2012), pancreatic 
cancer (Biankin et al., 2012), and melanomas (Martin et al., 2013; Cancer Genome Atlas 
Network, 2015; Hintzsche et al., 2017). It is a member of the U2 complex and, along with 
SF3B3 and PHF5A, binds to the branch point nucleotide in the pre-catalytic spliceosome 
(Yan et al., 2016). Here, in a global survey of SF3B1 mutations pan-cancer, we found 
somatic hotspot mutations that appear to cluster in the C-terminal HEAT repeat domains 
(HDs) 4–12 (Figures 2A and 2B; Table S2). We previously reported that hotspot mutations 
in HDs 4-8 display aberrant splicing events enriched with alternative 3′ splice sites (ss), 
likely as a result of reduced branchpoint fidelity (Darman et al., 2015). Here we also 
uncovered hotspot mutations in HDs 9-12, including p.L833 (HD 9) in LAML, p.E902 (HD 
11) in BLCA, and p.R957 (HD 12) in endometrial cancer (UCEC) samples. These hotspots 
appeared to be present mainly in these 3 tumor types, resembling previous observations of 
SF3B1 mutations in position p.R625, which are primarily observed in melanomas.
We observed that overall the occurrence of hotspot mutations in SF3B1 follows a specific 
periodicity of ~40 amino acids, suggesting a functional role for residues at these positions. 
Interestingly, the majority of these positions are located at the edge of the HEAT repeat 
helices of the SF3B1 protein structure (Figure 2B) (Yan et al., 2016; Cretu et al., 2016), 
suggesting they are important for interactions with RNA or protein or for the conformational 
flexibility of this super-helical domain. Previously discovered hotspot mutations cluster in 
HDs 4-8 and near the pre-mRNA-binding region, however, the hotspot mutations in HDs 
9-12 are located away from this region, raising the possibility they might induce unique 
splicing abnormalities.
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To test this hypothesis, we used the z-normalized percent spliced-in (PSI) of published 
alternative 3′ ss associated with SF3B1 hotspot mutations in HDs 4-8 (Darman et al., 2015) 
to stratify all TCGA solid tumor patient samples using principal-component analysis (PCA) 
(Figures 2C and S2A). We found that samples with previously identified hotspot mutations 
in HDs 4-8 were separated from SF3B1 wild-type (WT) samples, as expected. Interestingly, 
samples with non-hotspot mutations in SF3B1 or mutations in hotspots in HDs 9-12 
including those with mutations at position p.E902, were mostly clustered with WT samples, 
indicating these mutations do not confer the same altered splicing phenotype. We then 
performed differential splicing analysis using RNA sequencing data directly comparing 
samples in BLCA with SF3B1 p.E902K (n = 6) to tumors of the same lineage, which were 
WT with respect to all splicing factor genes (n = 40), resulting in 134 significantly altered 
junctions (Figure 2D; Table S3). Though splicing alterations as a result of p.E902K also 
favored alternative 3′ ss, the selected 3′ ss were preferentially located downstream of the 3′ 
ss used in the WT, while 3′ ss promoted by previously observed hotspots were mostly found 
upstream (Figure 2E). Similar to 3′ ss promoted by previously identified hotspot mutations, 
alternative 3′ ss and exon inclusion junctions promoted by SF3B1 p.E902K were also able 
to stratify solid tumor samples distinctly from samples with other SF3B1 mutations (Figure 
S2B). The p.R957Q mutation was found to be co-occurring with POLE mutations in UCEC 
and, thus, in samples with very high mutation rates, reducing the likelihood that this specific 
SF3B1 mutation is functionally relevant. Other hotspots, such as p.L833, did not have 
enough samples to allow further functional validation of potential splicing alterations.
U2AF1 and SRSF2 Hotspot Mutations Confer Altered Splicing Based on Sequence 
Features
Hotspot mutations of U2AF1 have been reported to alter exon inclusion ratios in both 
leukemia and lung adenocarcinoma (Przychodzen et al., 2013; Brooks et al., 2014). U2AF1, 
like SF3B1, is associated with the U2 complex, and it is known to recognize the 3′ 
dinucleotide AG; and, along with its partner U2AF2 that binds to the 3′ poly-Y tract, it 
promotes assembly of the pre-catalytic spliceosome (Wu et al., 1999). Hotspot mutations at 
amino acid positions p.S34 and p.Q157 are common in hematological malignancies 
(Papaemmanuil et al., 2013; Lindsley et al., 2015) and confer distinct splicing phenotypes 
(Ilagan et al., 2015), affecting exon inclusion rates based on the nucleotide in the −1 and +1 
position relative to the 3′ AG dinucleotide, respectively. In TCGA, p.S34F/Y is the 
dominant hotspot mutation and is observed in multiple tumor types, most notably LAML, 
LUAD, and UCEC (Figure 3A; Table S2). In contrast, U2AF1 mutations at p.Q157 are rare 
and occur in only two samples.
To explore the functional impact of the U2AF1 p.S34 hotspot mutations, we focused on 
LUAD and LAML, comparing mutant samples (n = 15 LUAD and n = 6 LAML) to samples 
with no known splicing factor gene mutation (n = 87 LUAD and n = 127 LAML). We 
observed an altered splicing phenotype dominated by alternative 3′ ss and cassette exon 
events, similar to results obtained by Brooks et al. (2014) (Figure 3B; Table S3). Both exon 
inclusion and exon skipping events were associated with reduced usage of the 3′ ss 
trinucleotide TAG, reflecting mutant preference for either C or A in the −1 position. 
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Interestingly, we also observed the same motif selection for alternative 3′ splicing events, 
which had not been previously reported (Figure 3C).
SRSF2 is an auxiliary splicing factor that has been shown to bind exonic pre-mRNA at 
specific motifs, where it acts as a splicing enhancer. Both hotspot mutations and in-frame 
deletions around position p.P95 have been reported, which increase mutant SRSF2 affinity 
to the nucleotide sequence CCNG relative to the sequence GGNG, resulting in altered exon 
inclusion rates (Zhang et al., 2015; Kim et al., 2015). We found the majority of SRSF2 
somatic mutations in LAML (n = 20) (Figure 3D; Table S2). Interestingly, we identified in-
frame deletions in UVM (n = 3), uncovering SRSF2 mutations in this disease. We confirmed 
that deletions around p.P95 (n = 2) also induced altered exon inclusion and exclusion as 
compared to WT samples (n = 20) (Figure 3E; Table S3), and we observed that exons with 
increased inclusion rates displayed an enrichment in CCNG versus GGNG sequence ratios 
(Figure 3F), consistent with published results in hematological tumors.
RBM10 LoF Mutation Is Associated with Exon Inclusion and a Corresponding Loss of 
Intron Retention Events in LUAD and BLCA
RBM10 is an RNA-binding protein associated exclusively with splicing repression (Wang et 
al., 2013), typically acting by binding in the intronic regions both up- and downstream of 
cassette exons. It is most frequently mutated in LUAD (Cancer Genome Atlas Research 
Network, 2014) and BLCA (Table S2), and the mutations are mutually exclusive with other 
splicing factor gene mutations (Figure 4A). RBM10 is located on the X chromosome, and its 
LoF mutations are the cause of the X-linked recessive disorder TARP syndrome, affecting 
mainly males (Johnston et al., 2010). We observed that RBM10 LoF mutations in LUAD 
were also associated with the male gender (p = 0.002, Fisher’s exact test), though this trend 
was not observed in BLCA, a disease that is found primarily in males. In both diseases, 
RBM10 LoF mutations resulted in reduced mRNA expression (Figure 4B; p value < 0.0001 
in all comparisons, Student’s t test). Differential splicing analyses comparing RBM10 LoF 
mutant tumors (n = 32) and samples WT for all splicing factor genes (n = 87) identified exon 
inclusion as the primary alternative splicing event in both LUAD and BLCA (Figure 4C; 
Figure S3A; Tables S2 and S3). This is consistent with earlier reports correlating the 
overexpression of RBM10 in HEK293 cells with exon skipping (Wang et al., 2013).
We observed a significant overlap in exons included following RBM10 loss in LUAD and 
exons previously reported to be both excluded upon RBM10 overexpression and included 
following knockdown (Figure S3B). Interestingly, RBM10 expression has also been shown 
to correlate with retention of the introns flanking the exons that are skipped due to its 
activity (Wang et al., 2013; Figure S3C), and we observed the corresponding normal splicing 
of these introns upon RBM10 loss in LUAD (Figure 4D). The majority of genes with this 
pattern of altered splicing by RBM10 LoF mutation were upregulated compared to RBM10 
WT samples, suggesting that RBM10-mediated cassette exon repression acts as an overall 
gene regulatory mechanism. We also observed that some RBM10-regulated exons contained 
a premature termination codon (PTC), which may cause the transcript to be targeted for 
nonsense-mediated decay (NMD) (Figure 4E). Genes predicted to contain these poison 
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exons were significantly more likely to be downregulated compared to other genes 
containing RBM10 LoF mutation-induced inclusion events (p = 1.07e–10, Kruskal H test).
FUBP1 LoF Mutation Is Associated with Cassette Exon Events and Gene Downregulation 
in LGG
FUBP1 (Far upstream element-binding protein 1) was initially described to regulate MYC 
through binding to its far-upstream element (FUSE), and its overexpression can stimulate 
MYC expression (Duncan et al., 1994; He et al., 2000). More recently, FUBP1 has been 
described to bind to AT-rich exons and mediate exon skipping via repression of splicing at 
the second step reaction (Li et al., 2013). FUBP1 is located at chromosome 1p, and its 
mutation co-occurs in a subset of glioma samples with 1p deletion. Co-deletion of 
chromosome 1p and 19q in glioma (Brat et al., 2015), in particular oligodendroglioma, is a 
common and early event (Jenkins et al., 2006). LoF mutations of FUBP1 in the remaining 
allele would result in complete loss of FUBP1 in diploid tumor cells. Indeed, we observed 
significant association of FUBP1 LoF mutation with the oligodendroglioma histology 
subtype, chromosome 1p deletion, and reduced FUBP1 gene expression in mutant samples 
compared to WT samples with 1p deletion (Figure 5A).
To investigate the effects of FUBP1 LoF mutations on aberrant splicing and gene expression, 
we defined our comparison groups to be FUBP1 LoF mutation positive (n = 30) versus WT 
(n = 31) under IDH1 mutation and chromosome 1p/19q deletion-positive background 
(Figure 5A; Table S4). Differential splicing analysis identified exon inclusion and exclusion 
as major alternative splicing events (Figure 5B; Table S3). The FUBP1 RNA expression 
level and copy number in U87MG, a glioblastoma cell line, are similar to our control LGG 
patient group, offering an experimental setting to validate our analysis from patient samples. 
We transfected U87MG cells with a pool of small interfering RNAs (siRNAs) against 
FUBP1, and we performed RNA sequencing. We first confirmed FUBP1 knockdown at both 
protein (Figure 5C) and mRNA (67% depletion) levels. Differential splicing analysis showed 
a similar distribution of aberrant splicing events between transient FUBP1 knockdown in 
U87MG cells and in FUBP1 LoF patients (Figure S4A; Table S3). Though the overlap of 
significant splicing events defined by the default q-value threshold of 0.05 was small among 
events detected in genes that were expressed in both patient samples and U87MG cells 
(11/155 events), splicing junctions upregulated upon FUPB1 loss in patient samples showed 
similar, though weaker, upregulation in U87MG (Figure 5D), confirming that the observed 
splicing changes were modulated by the loss of FUBP1 (p value 4.38e–37, binomial test).
Mechanistically, FUBP1 has been shown to preferentially bind to and inhibit AT-rich exons 
(Li et al., 2013), and to explore this relationship we calculated the average AT content 
profiles of the cassette exons and the flanking two exons. Compared to background, we 
observed significantly higher AT content in all 3 exons of exon-skipping events (p < 0.00015 
in all three comparisons, Student’s t test) (Figure S4B), an observation that was recapitulated 
in FUBP1 siRNA-treated U87MG cells (p < 0.00019 in all three comparisons, Student’s t 
test) (Figure S4C). Although not statistically significant, we also observed that exons 
promoted by mutant samples (exon inclusion events) had higher AT content near their 5′ 
ends compared to exons preferentially included by WT samples, perhaps contributing to this 
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phenotype. Overall, genes with alternative splicing events of any type in patient samples (n = 
163) were significantly more likely to be downregulated compared to background (n = 
22,982; p = 4.7e–34, Kruskal H test) (Figure 5E), and, among these spliced genes, we 
observed that those with events predicted to result in a transcript degraded by the NMD 
pathway were downregulated further (p = 3.0e–4, Kruskal H test).
Given the proposed association between FUBP1 and MYC expression regulation, we also 
evaluated the potential functional consequences of FUBP1 LoF on MYC expression and 
downstream MYC signaling. Though we did not see significant reduction in MYC 
expression, there was a significant downregulation of MYC target genes associated with 
FUBP1 LoF mutations (Figure S4D; Table S5). We did not observe any MYC target genes to 
be alternatively spliced, indicating this downregulation was independent of FUBP1 
functional splicing alterations. Interestingly, we observed that MYC target gene changes 
were also correlated in U87MG cells treated with siRNA against FUBP1 (Figure S4E), 
confirming the independent association between FUBP1 loss and MYC activity.
Driver Mutations in Splicing Factors Affect Cancer Cell-Autonomous Pathways and 
Immune Infiltration
While extensive studies have characterized the splicing aberrations associated with well-
known splicing factor gene mutations, the understanding of how these mutations and 
splicing changes contribute to selective advantages during tumorigenesis remains unclear. 
Repeated observations of mutual exclusivity between different splicing factor driver 
mutations within the same disease (Figure 4A) (Papaemmanuil et al., 2013; Haferlach et al., 
2014; Lindsley et al., 2015) suggest either their functional convergence at the pathway level 
or that cells cannot tolerate more than one splicing factor driver mutation. Hence, we 
conducted systematic pathway analysis in tumor types harboring driver mutations of the five 
genes (SF3B1, SRSF2, U2AF1, RBM10, and FUBP1) with confirmed on-target splicing 
deregulation (Figure 6A).
First, we performed gene set enrichment analysis (GSEA) using 50 hallmark gene sets 
(Subramanian et al., 2005) by comparing all mutant samples of each gene versus their WT 
control group, which was carefully selected to remove confounding factors of tumor subtype 
and other splicing factor gene mutations (Table S4). We then clustered all comparison 
groups and hallmark gene sets using normalized enrichment scores (NESs) (Figure S5A; 
Table S5). We observed that comparison groups generally clustered by tumor type or similar 
cell lineage, rather than by specific splicing factor mutations. For example, U2AF1 hotspot 
mutations in LUAD and RBM10 LoF mutations in epithelial tumors BLCA and LUAD 
group together, while SF3B1 hotspot mutations in melanomas SKCM and UVM and SRSF2 
hotspot mutations in UVM group together. Moreover, certain splicing factor mutations in 
specific tumor types tended to associate with broad downregulation of cancer hallmark 
genes, such as SF3B1 hotspot mutations in SKCM and UVM, whereas SF3B1 mutations in 
BRCA and U2AF1 in LAML were associated with broad upregulation of the same 
hallmarks. This prompted us to further identify cancer hallmarks commonly regulated by 
different splicing factor gene mutations in the same tumor type. Within cohorts, hallmark 
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gene sets related to immune response, cell cycle checkpoint and DNA damage response 
(DDR), and metabolism were associated with splicing factor mutations (Figures S5B–S5E).
Since hallmark gene sets tend to be broadly defined, we also conducted enrichment analysis 
using a set of custom gene sets containing more specific gene signatures of the hallmark 
pathways uncovered above. In addition, we included spliceosome, ribosome, proteasome, 
histone, and NMD pathway genes due to their functional relevance to the splicing process 
(Table S6). We then re-clustered comparison groups and gene sets using the NESs of these 
curated gene sets (Figure 6B; Table S7). Strikingly, this analysis revealed that gene sets can 
be clustered into two large groups: group 1 (colored green in Figure 6B) contains mostly 
cell-autonomous gene signatures of cell cycle, DDR, and essential cellular machineries; and 
group 2 (colored purple in Figure 6B) is composed of immune cell signatures. Among cell-
autonomous gene sets (Figures 6B and 6C), proteasome genes were upregulated in multiple 
comparison groups. Ribosomal genes were strongly upregulated in SF3B1 hotspot mutants 
within SKCM and both SF3B1 and SRSF2 mutants in UVM, three subsets associated with 
general downregulation of most gene sets. Cell cycle-related gene sets tended to be more 
consistently upregulated in the splicing factor mutant samples of BLCA and LUAD (Figures 
6B and 6C). Among immune cell signatures, we found that certain subgroups, and in 
particular FUBP1 in LGG, were associated with broad upregulation, suggesting that these 
conditions harbor an increased immune infiltration. Alternatively, multiple T cell signatures 
were consistently downregulated in SF3B1 mutants of UVM as well as splicing factor 
mutant subsets of BLCA and LUAD, suggesting that splicing factor mutations in these 
tumor types were associated with fewerT cell infiltrates. To test the hypothesis that the low 
immune cell enrichment scores are most likely due to less immune infiltrates in the tumor 
microenvironment, we compared lung adenocarcinoma cell lines with RBM10 LoF 
mutations to the WT (Table S4), and we compared the result with that from LUAD samples 
(Figure 6D). Three ribosome signatures were significantly upregulated in both comparisons, 
and other cell-autonomous signatures trended very similarly. However, we observed that 
most immune cell signatures were only significantly downregulated in patient tumor samples 
and not in cell lines. Since cancer cell lines are devoid of immune cells, we infer this is most 
likely due to reduced immune infiltrates in the tumor microenvironment.
DISCUSSION
Using matched DNA and RNA sequencing, we have surveyed 33 tumor types for somatic 
mutations of over 400 splicing factor genes, and we identified 119 with putative driver 
mutations. We observed that the most common mutations are mutually exclusive in each 
cohort, similar to prior hematological surveys (Papaemmanuil et al., 2013; Haferlach et al., 
2014; Landau et al., 2015), and furthermore induce altered splicing, which is consistent 
across tumor lineages. Though splicing factor gene mutations were observed in all tumor 
types, we found that BLCA and UVM had a significantly higher frequency of putative driver 
mutations compared to other cohorts. Together, these results suggest that splicing 
deregulation by somatic mutation in cancer is broader than previously reported.
Curiously, though hotspot mutations in SF3B1 were found in several cohorts, we observed 
striking lineage specificity for certain amino acid changes. Melanomas of both SKCM and 
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UVM strongly prefer p.R625C/H (21/33 non-silent mutations in HDs 4-12), while BRCA 
strongly prefer p.K700E (10/18 nonsilent mutations in HDs 4-12), the same most frequently 
mutated position in hematological malignancies, and p.E902K is only observed in BLCA. 
Lineage-specific hotspot mutations are likely the outcome of the interplay of several 
contributing factors, including nucleotide context mutability, gene-specific mutation rate in 
the tumor type, lineage-specific interacting partner proteins of a protein complex, and the 
mutational impact on cancer genes and pathways to confer survival advantage in a particular 
type of cancer. Deconvoluting these complex interactions will be essential to understand the 
selective pressures underlying these mutations.
How splicing factor gene mutations confer selective advantage to tumor cells is an area of 
active study. Since splicing factor gene mutations are likely to induce broad transcriptome 
changes, it is possible these changes can include splicing of oncogenes and tumor 
suppressors. In hematological malignancies, it has been demonstrated that somatic hotspot 
mutations in SRSF2 leads to mis-splicing and degradation of EZH2 (Kim et al., 2015), a 
gene known to be recurrently mutated in those diseases. In another study, SF3B1 mutations 
in chronic lymphocytic leukemia (CLL) were shown to lead to mis-splicing and the 
production of a truncated form of ATM, another gene frequently mutated in CLL (Ferreira et 
al., 2014). In both cases, these splicing factor mutations have been shown to be mutually 
exclusive with mutations of the aberrantly spliced target gene. In our analysis, we observe 
previously reported altered splicing of various cancer genes induced by splicing factor gene 
mutations, including EZH2 in LAML SRSF2 hotspot mutants and NUMB in LUAD RBM10 
LoF mutants (Bechara et al., 2013). We also find additional unreported cancer gene 
alterations. For example, SF3B1 hotspot mutations in BRCA are associated with mis-
splicing of CDH1, a gene with frequent LoF mutations in invasive lobular breast cancer 
(Desmedt et al., 2016). In another example, both RBM10 LoF and U2AF1 hotspot mutants 
in LUAD are associated with TSC2 mis-splicing, a tumor suppressor of the mTOR pathway 
(Krymskaya, 2003).
Given the multitude of genes impacted by mis-splicing due to splicing factor gene 
mutations, the downstream functional impact is unlikely to be solely due to the altered 
splicing of a single cancer gene. Instead, splicing factor mutations may cause a 
transcriptome-wide deregulation of normal splicing (spliceosome sickness), which induces 
broad transcriptional programs beneficial to the tumor. Overall, we observed that different 
splicing factor genes in the same tumor types are much more likely to be associated with 
deregulation of the same cancer pathways. These results support the idea that the observed 
mutual exclusivity of putative driver mutations within a tumor type might be due to 
functional redundancy, though we cannot rule out that co-occurrence of these mutations may 
be lethal. Previous functional studies of splicing factor mutations in SF3B1 and U2AF1 
using non-hematological tumor cell lines (Zhou et al., 2015; Fei et al., 2016) indicated that 
the mutant allele is not essential for cell survival and does not provide a proliferation 
advantage in vitro. Our pathway analysis suggests that, in certain solid tumors, splicing 
factor mutations are associated with reduced immune infiltration and, therefore, may provide 
selective advantage to cancer cells through immune evasion. Unlike SF3B1 and U2AF1, 
RBM10 has been reported to regulate splicing of apoptosis and notch pathway genes, and 
functional studies of cancer cell lines in vitro and in vivo show that LoF mutations lead to 
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enhanced colony formation or accelerated tumor growth (Bechara et al., 2013; Hernández et 
al., 2016; Zhao et al., 2017). Our analysis comparing RBM10 LoF mutations in tumor 
samples and in cancer cell lines complements the existing studies, and it proposes that loss 
of this splicing factor has an immunosuppressive role in addition to its cell-autonomous 
growth-promoting role.
Cancer-specific splicing changes are increasingly recognized to contribute to tumorigenesis 
via various mechanisms. Multiple oncogenes and tumor suppressors have been reported to 
express cancer-specific or treatment-resistant splice variants (Zhang and Manley, 2013). In 
another survey of the extent of somatic single-nucleotide variants (SNVs) altering splicing, a 
large number of SNVs are found to cause intron retention in tumor suppressors and loss of 
function through NMD or truncated proteins (Jung et al., 2015). Alternatively, splicing 
factors can act as proto-oncogene or tumor suppressors when their expression is altered in 
cancer (Anczukow et al., 2015; Jiang et al., 2016). The spectrum of splicing factor gene 
mutations that occur in multiple tumor types highlights somatic mutation as an important 
mechanism of splicing deregulation in cancer, the scope of which we are just starting to 
uncover. Collectively, these observations suggest deregulated RNA splicing as a hallmark of 
cancer. More functional studies are clearly needed to understand the impact of RNA-splicing 
changes and splicing factor mutations and, most importantly, their contribution to cancer 
development.
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Lihua Yu (Lihua_Yu@h3biomedicine.com).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines—U87MG (male, glioblastoma) cells were obtained from ATCC (ATCC 
HTB-14) and cultured in ATCC-formulated Eagle’s Minimum Essential Medium (30-2003) 
supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2 and 95% humidity. 
Cell authentication was conducted at IDEXX BioResearch using STR DNA profiling and 
found to be 100% matching markers listed in the ATCC database for U87MG cells, with no 
species contamination.
METHODS DETAILS
Compilation of splicing factor genes—We collected 1512 spliceosome and splicing 
related genes from three sources: 1)244 spliceosome proteins reported in (Hegele et al., 
2012) from a comprehensive yeast two hybrid study using spliceosome components as bait, 
2) 254 splicing factors and splicing related proteins annotated in (Barbosa-Morais et al., 
2006) Table S6, and 3) 1100 genes from SpliceosomeDB (Cvitkovic and Jurica, 2013). The 
latter two are curated component lists derived from other publications. All gene identifiers 
are standardized into HUGO symbol and EntrezID. We prioritized the final list of 404 
splicing factor genes (Table S1) by including all genes from sources 1) and 2), and genes 
from 3) if they are annotated in as “complex-SpliceosomeDB” or “class/family-
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SpliceosomeDB” excluding “common MS contaminants,” or if they belong to the same 
protein families from any genes above. The reason we used this conservative approach to 
prioritize genes in 3) is that some genes, though identified by mass spectrometry 
experiments in certain spliceosomes, have undefined functions and orthologs across species 
and hence could simply be contaminants in sample preparations found associated with 
human spliceosomes.
Detection of somatic mutation and identification of splicing factor genes with 
driver mutations—Somatic mutation data was provided by TCGA MC3 working group 
(see Key Resources Table). We considered a sample “splicing factor WT” (and therefore 
appropriate for use in differential splicing or gene expression contexts) if there were no non-
silent mutations in any known splicing factor genes.
MutSigCV analytical results were downloaded from Broad TCGA Firehose dashboard on 
September 2016 (https://confluence.broadinstitute.org/display/GDAC/Dashboard-Analyses). 
MutSig2CV3.1 results were used when available. A q-value cut-off of 0.1 was used to define 
significantly mutated genes in each cohort. We excluded PAAD cohorts from this analysis as 
samples in this cohort typically had extremely low non-silent mutation counts.
For the ratiometric method, we defined mutational hotspots (HS) as missense or in-frame 
deletion mutations at the same protein position > = 3 pan-TCGA. Loss of function (LoF) 
mutations were defined as any of the following mutation classifications (Frame_Shift_Del, 
Frame_Shift_Ins, Nonsense, Splice_Site). We then calculated %HS or %LoF as the total 
number of hotspot or LoF mutation-positive samples divided by total number of non-silent 
mutations per gene per cohort. The “pancan” cohort encompasses all samples in TCGA. We 
used empirical cut-offs to define genes as HS or LoF type, specifically:
If %HS > = 30% and %LoF ≤ 20% and HS counts > = 3, a gene is called “hotspot” in that 
cohort, and if %LoF > = 30% and %HS ≤ 20% and LoF mutation counts > = 10, a gene is 
called “LoF” type in that cohort.
An extended ratiometric method published by Tokheim et al. (Tokheim et al., 2016) called 
“20/20+” was used as an additional evaluator of putative driver splicing factors. This method 
uses a random forest-based method trained on known cancer driver genes to identify cohort-
level cutoffs appropriate for this identification. For each cohort (as well as the “pancan” 
cohort), the pre-trained random forest classifier provided by Tokheim et al. was used to 
assign Benjamini-Hochberg corrected q-values to each gene with q < 0.1 used as a cutoff for 
significance. These results are given in Table S1. All genes were plotted using oncogene 
score and tumor suppressor gene score provided by 20/20+, with significant genes labeled 
and colored based on the larger of the two scores (i.e., red genes have higher oncogene score 
than tumor suppressor score, whereas blue genes the opposite) (Figure S1C).
Detection of additional samples with hotspot mutations of SF3B1, U2AF1, and 
SRSF2—Following read alignment by STAR allowing multimapping reads of RNaseq files, 
samples were interrogated for functional hotspot mutations in known driver splicing genes 
SF3B1, U2AF1, and SRSF2. For SF3B1, amino acids p.E622, p.Y623, p.R625, p.N626, 
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p.H662, p.T663, p.K666, p.K700, p.V701, p.I704, p.G740, p.K741, p.G742, and p.D781 
(Darman et al., 2015, Obeng et al., 2016) were used. For U2AF1, amino acids p.S34, 
p.R156, and p.Q157 were used (Papaemmanuil et al., 2013; Lindsley et al., 2015). For 
SRSF2, mutations and deletions in/near amino acid p.P95 were used (Zhang et al., 2015, 
Kim et al., 2015). Samtools (Li et al., 2009) mpileup was used for genotyping, and only 
uniquely mapped reads were allowed. A minimum total read coverage of 10 was imposed 
for the codon encoding amino acid changes in these genes as well as a minimum read 
coverage of 4 supporting the change. Mutations with allele frequency < 5% were ignored. 
We also performed visual inspection using Integrative Genomic Viewer (IGV, Robinson et 
al., 2011) and indel mis-calls were manually corrected.
Prioritization of genes for differential splicing and pathway analysis—We 
prioritized two groups of genes for in-depth differential splicing and pathway analysis. 
Group 1 includes SF3B1, SRSF2 and U2AF1. Driver mutations of these genes are well 
reported with high frequency in hematological tumors and their associated splicing changes 
are well studied. The goal is to understand how similar or potentially different their somatic 
mutations and their associated splicing changes are pan-cancer. Group 2 includes other 
genes with exceptional high mutation frequency and compelling hotspot or LoF mutation 
patterns. RBM10 and FUBP1 are the top 2 splicing factor genes by frequency of mutation, 
both with a strong LoF mutation pattern.
Principal component analysis of mutant and wild-type splicing factor samples
—Junction counts for all TCGA samples were obtained from Omicsoft® OncoLand® 2016 
Q2 release and converted to PSI. SF3B1 mutation information was obtained from TCGA 
pan-cancer MC3 data and validated using RNA-Seq data. Alternative 3′ splice sites 
promoted by SF3B1 mutant (HD4-8) activity were obtained from Darman et al., 2015 
(Darman et al., 2015). Alternative 3′ splice sites and exon inclusion events promoted by 
SF3B1 p.E902K versus splicing factor WT samples in BLCA (Table S3) are used to stratify 
patient samples in Figure S2B.
Letter-value plot—Letter-value plots (Hofmann et al., 2017) are an extension of the 
standard boxplot for large-scale data. The seaborn python package (see Key Resources 
Table) was used with the depth parameter “proportion,” where 0.007 is assumed the fraction 
of samples which are outliers in a given cohort. Letter-value boxes (percentiles of the data, 
which start at 50% and decrease by half each iteration) are drawn until this fraction is 
reached. Boxes are colored based on the density of points within, where darker colors 
indicate higher density.
Pathway analysis—Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) 
was performed using cancer hallmarks and the curated gene sets. Default parameters were 
chosen except the minimum gene set size was set to 5. The gene expression for each cohort 
was defined as the mean Log2 transcripts per million (TPM) (i.e., log2(1+tpm)). The R 
package limma (Ritchie et al., 2015) was used for differential gene expression analysis after 
filtering out low-expressed genes (maximum TPM < 3), and gene lists ranked by moderated 
t-statistic values were used as input for GSEA.
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Clustering analysis of normalized enrichment score (NES) was done using the R (R 
Development Core Team, 2011) package using heatmap software from (https://
raw.githubusercontent.com/obigriffith/biostar-tutorials/master/Heatmaps/heatmap.3.R)
Curation of gene sets (Table S6)—The following custom gene sets for enrichment 
analysis:
1. Cell cycle gene sets were obtained from QIAGEN human cell cycle PCR array 
Cat. No. PAHS-020Z (http://www.sabiosciences.com/rt_pcr_product/HTML/
PAHS-020Z.html).
2. DNA damage response/repair (DDR) gene sets were shared with us by TCGA 
PanCanAtlas DDR analysis working group.
3. Immune gene sets were obtained from the publication by Newman et al., 2015.
4. Proteasome gene set was obtained from HUGO Gene Nomenclature Committee 
(HGNC) under gene family proteasome (http://www.genenames.org/cgi-bin/
genefamilies/set/690) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
proteasome (http://www.genome.jp/kegg/pathway/hsa/hsa03050.html).
5. Ribosome gene sets were obtained from Ribosomal Protein Gene Database 
(RPG) (http://ribosome.med.miyazaki-u.ac.jp/) and KEGG ribosome (http://
www.genome.jp/kegg/pathway/hsa/hsa03010.html).
6. Spliceosome is in Table S1.
7. Nonsense mediated decay (NMD) gene set was curated based on two 
publications (Nicholson et al., 2010; Kervestin and Jacobson, 2012).
8. Histone gene list were obtained from HUGO Gene Nomenclature Committee 
Histone gene family (http://www.genenames.org/cgi-bin/genefamilies/set/864)
9. Antigen presentation gene set was from Reactome: (http://
software.broadinstitute.org/gsea/msigdb/cards/
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_P
EPTIDE_LOADING_OF_CLASS_I_MHC.html). It captures the key elements, 
while excluding things that are redundant from other customer gene lists (e.g., 
proteasome).
FUBP1 Knockdown in U87MG and RNA Sequencing—U87MG cells were obtained 
from ATCC (ATCC HTB-14) and cultured in ATCC-formulated Eagle’s Minimum Essential 
Medium (30-2003) supplemented with 10% FBS. ON-TARGETplus Non-targeting siRNA 
Pool (D-001810-10-05) and ON-TARGETplus Human FUBP1 siRNA SMARTpool 
(L-011548-00-0005) were obtained from Dharmacon. To knockdown FUBP1,250,000 
U87MG cells were seeded per well in six-well plates. On the second day, either the non-
targeting siRNA pool or the human FUBP1 siRNA pool was transfected into U87MG cells 
in quadruplicates using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher 
Scientific), according to the manufacturer’s manual. The final concentration of the siRNA 
pool was 50 nM in each well; 3 days after transfection, medium was refreshed. At 5 days 
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post-transfection, one well of either non-targeting siRNA pool- or FUBP1 siRNA pool-
transfected cells was harvested in radio immunoprecipitation assay (RIPA) buffer 
supplemented with proteasome complete protease inhibitor cocktail and PhosStop 
phosphatase inhibitor cocktail (Roche Life Science) for western blot analysis to examine the 
knockdown efficiency. Specially, equal amounts of protein lysates were loaded onto 
4%-12% NuPAGE Bis-Tris gels (Thermo Fisher Scientific) before being transferred onto 
Nitrocellulose membrane using the iBlot2 dry blotting system (Thermo Fisher Scientific). 
The membrane was blocked with LI-COR buffer and then incubated with rabbit polyclonal 
anti-FUBP1 antibody (Abcam ab181111) and monoclonal anti-GAPDH antibody (Sigma 
G8795) overnight in a cold room. On the second day, the membrane was washed three times 
with tris-buffered saline Tween 20 (TBST) and incubated with LI-COR IRdye secondary 
antibodies before TBST wash, and it was scanned and quantified using LI-COR Odyssey 
imaging system. For RNA extraction, the remaining three wells for each transfection were 
harvested with RNeasy lysis buffer, and total RNAs were extracted using RNeasy column kit 
(QIAGEN), following the manufacturer’s protocol. Extracted total RNAs were analyzed on 
Agilent Tapestation to ensure RNA quality before being submitted to Beijing Genomic 
Institute (BGI) for polyA+ RNA sequencing (RNA-seq) library preparation and sequenced 
on Illumina Hiseq 4000.
Differential Splicing Analysis and NMD Prediction—Differential splicing analysis 
was performed similar to previously described methodology (Darman et al., 2015). In brief, 
raw sequence reads were extracted from BAM files made available through TCGA, then 
aligned using STAR using two-pass alignment (Dobin et al., 2013) to human reference 
genome GRCh37/hg19. Junction PSI was calculated for all sets of junctions that shared a 
single common ss as the number of raw reads supporting that junction divided by the total 
number of reads in all junctions sharing that ss. We accounted for intron retention in PSI 
calculations by counting reads that completely overlapped a 6-nt window around the ss (3 nt 
within the intron and 3 nt within the exon) as intron retention reads. Read count for each 
junction was pooled in the FUBP1 siRNA versus non-targeting siRNA cell line comparison 
to increase statistical power. Each PSI measurement was converted to log odds via the 
formula log(p/(1-p)) before being compared using either a moderated t test (Ritchie et al., 
2015) (patient samples) or binomial test (cell lines) between cohorts. False discovery rate 
(FDR)-corrected q-values < 0.05 for junctions promoted by the case or mutant cohort 
(alternative junction) were considered significant. To be reported as a splicing event, at least 
one junction promoted by the control, orWT case (canonical junction[s]), that shared an ss 
with the alternative junction was also required to have an FDR-corrected q-value < 0.2, and 
these are reported in Table S3. For intron retention events, both 5′ and 3′ exon-intron 
boundaries were required to be significant, and a minimum median threshold for mean 
intron read coverage over all samples in that cohort was set at 0.1 in order to reduce false 
positives. NMD prediction was performed for each splicing event by first identifying all 
RefSeq transcripts that contained an intron that shares an ss with the mutation-promoting 
junction and then determining the novel peptide sequence that resulted from altering that 
transcript to contain the splicing event (Darman et al., 2015). Events were predicted to be 
NMD-targeted if all affected transcripts contained a stop codon > 50 nt from the final exon-
exon junction.
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QUANTIFICATION AND STATISTICAL ANALYSIS
The details of each statistical test are contained within the Results, including the total 
number of samples (n) in each case and control condition, as well as the test used. Unless 
otherwise specified, p values less than 0.05 were considered significant. Multiple testing 
correction was performed where applicable using the Benjamini-Hochberg FDR correction, 
and q-values less than 0.05 were considered significant unless otherwise specified.
Differential Gene Expression—Gene differential expression was performed using the 
limma package following quantification using Kallisto (Bray et al., 2016).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA sequencing data from U87MG cells reported in this 
paper is GEO: GSE100530. All other data used are available from the Genomic Data 
Commons (https://portal.gdc.cancer.gov/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• 119 splicing factor genes carry putative driver mutations in one or more 
cancer types
• BLCA and UVM carry more driver splicing factor mutations than expected by 
chance
• Common splicing factor mutations associated with lineage-independent 
altered splicing
• Mutations are associated with deregulation of cell-autonomous pathways and 
immune infiltration
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Figure 1. 119 Splicing Factor Genes Are Mutated across All Tumor Cohorts
(A) Prioritization of splicing factor genes with likely driver mutations.
(B) Hotspot (HS)- (red) and loss-of-function (LoF)- (blue) mutated genes in the pancan 
cohort are mapped to spliceosome complexes. The percent non-silent mutation frequency 
(Table S1) is listed next to each gene.
(C) Genes are plotted as %hotspot or %LoF mutations for non-silent mutations across 
TCGA (pancan). OG-like genes are colored red and TSG-like genes are colored blue.
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(D) Heatmap view of %hotspot (bottom orange panel) or %LoF mutations (top blue panel) 
of all non-silent mutations per gene in each tumor cohort, sorted by % hotspot mutation high 
to low and %LoF mutation low to high from left to right. Tumor cohorts are sorted by 
average mutation counts per sample (right green bar). For comparison, the fraction of 
samples with non-silent mutations in any of the 119 genes are shown as purple bars on the 
right. The number of samples with any non-silent mutation in each likely driver gene is 
given in the top bar chart.
See also Figure S1 and Table S1.
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Figure 2. SF3B1 Hotspot Mutations across Multiple Tumor Types
(A) SF3B1 somatic mutations in HDs 4-12. Each dot represents a mutant sample colored by 
tumor cohort.
(B) SF3B1 hotspot mutations are mapped to the structure (PDB: 5GM6). Hotspots in HDs 
4-8 are colored purple whereas hotspots in HDs 9-12 are colored gold.
(C) PCA stratifies samples from all solid tumor cohorts with SF3B1 mutations using the 
expression of alternative 3′ ss associated with SF3B1 hotspot mutations in HDs 4-8. Purple, 
samples with hotspot mutations in HDs 4-8 (n = 57); gold, samples with p.E902 (n = 7) and 
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p.R957 (n = 5) mutations; green, samples with missense mutations in all other locations (n = 
203); gray, WT samples (n = 8,811).
(D) Differential splicing events associated with the BLCA-specific SF3B1 p.E902K 
mutation (corrected q-value < 0.05). Below each splicing event count, the PSI log2 fold 
change of each individual event is detailed in a boxplot.
(E) Kernel density estimation plots showing the location of alternative 3′ ss AGs with 
respect to canonical 3′ ss AGs preferentially used by hotspot mutations in HDs 4-8 (purple) 
or p.E902K in BLCA (gold).
See also Figure S2 and Tables S2 and S3.
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Figure 3. U2AF1 and SRSF2 Mutations in the Pancan Cohort and Differential Splicing 
Associated with Hotspot Mutations
(A) U2AF1 somatic mutations mapped to amino acid positions and annotated domains. Each 
dot represents a single mutant sample colored by tumor cohort.
(B) Differential splicing events associated with U2AF1 p.S34F/Y hotspot mutations in 
LUAD and LAML (corrected q-value < 0.05). Below each splicing event count, the PSI log2 
fold change of each individual event is detailed in a boxplot.
(C) Consensus sequence motifs for exons preferentially used by mutant U2AF1 versus WT 
U2AF1 across various alternative splicing events.
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(D) SRSF2 somatic mutations mapped to amino acid positions and annotated domains. Each 
bar (in-frame deletion) and dot (other mutations) represents a singlemutant sample colored 
by tumor cohort.
(E) Differential splicing events associated with SRSF2 in-frame deletions in UVM.
(F) Tetramer (CCNG and GGNG) enrichment analysis comparing cassette exons 
preferentially included or excluded by SRSF2 mutant samples. Each value is the average 
tetramer occurrence frequency for all exons in that class. Fold change significance was 
assessed using Student’s t test.
See also Tables S2 and S3.
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Figure 4. RBM10 LoF Mutations Detected in LUAD and BLCA Induce Global Exon Inclusion 
Events
(A) RBM10 LoF mutations are mutually exclusive from other splicing factor gene mutations 
in LUAD and BLCA.
(B) LoF mutations in RBM10 lead to reduced mRNA expression in both LUAD and BLCA. 
Each point depicts a sample and the boxplot whiskers depict the complete data range. ****p 
< 0.0001 in all comparisons, Student’s t test.
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(C) Differential splicing events associated with RBM10 LoF mutations in LUAD (corrected 
q-value < 0.05). Below each splicing event count, the PSI log2 fold change of each 
individual event is detailed in a boxplot.
(D) Exon inclusion is often concomitant with intron splicing associated with RBM10 LoF 
mutation in LUAD.
(E) Exons promoted by RBM10 LoF mutation in LUAD may be predicted to contain PTCs 
(red), leading to reduced gene expression compared to those that do not (blue).
See also Figure S3 and Tables S2 and S3.
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Figure 5. FUBP1 LoF Mutations in LGG and Associated Differential Splicing
(A) FUBP1 LoF mutations are primarily associated with IDH1 mutation and the 
oligodendroglioma histology in LGG.
(B) Differential splicing events associated with FUBP1 LoF mutations in LGG (corrected q-
value < 0.05). Below each splicing event count, the PSI log2 fold change of each individual 
event is detailed in a boxplot.
(C) Western blot of FUBP1 protein following transfection of FUBP1 siRNA pool or non-
targeting (NT) siRNA pool.
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(D) Log2 fold change of splice junctions identified in LGG patient samples (n = 155) in 
U87MG (blue) compared to LGG patient samples (red).
(E) Letter-value plot showing that genes with alternative splicing events in LGG patient 
samples (n = 163) are significantly downregulated compared to background (n = 22,982), 
and genes with splicing changes predicted to result in transcripts targeted by the NMD 
pathway (n = 79) are significantly downregulated compared to genes not predicted to be 
targeted (n = 94). The y axis data range has been terminated at −5, +5 for clarity.
See also Figure S4 and Tables S3 and S4.
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Figure 6. Pathway Enrichment Analysis Using Curated Gene Sets Indicates that Cancer 
Pathways Altered by Splicing Factor Mutations Are Lineage Specific
(A) Splicing factor gene mutations and their associated tumor cohorts used in pathway 
analyses.
(B) Heatmap of gene set enrichment analyses for all comparison groups generated using 
normalized enrichment scores (NESs) of 46 curated gene sets. Two distinct subclasses of 
gene sets are cell-autonomous pathways (green) and immune-related signatures (purple).
(C) Representative cancer hallmark gene sets upregulated in splicing factor mutant samples.
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(D) Heatmap of NESs comparing patient tumor samples and cell lines, where each column 
represents the differential pathway modulation of RBM10 LoF mutants (n = 27 TCGA, n = 
3 cell lines) versus RBM10 WT (n = 20 TCGA, n = 30 cell lines) of 46 curated gene sets. 
Significantly modulated gene sets (q value ≤ 0.05) are highlighted with an asterisk.
See also Figure S5 and Tables S4, S5, S6, and S7.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-FUBP1 
antibody
Abcam Abcam# ab181111
Deposited Data
Raw and analyzed data This paper GEO: GSE100530
Human reference genome 
NCBI build 37, GRCh37
Genome Reference Consortium http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/
GENCODE v19 GENCODE https://www.gencodegenes.org/releases/19.html
RefSeq NCBI https://www.ncbi.nlm.nih.gov/refseq/
Raw TCGA and CCLE RNA-
Seq data
Genomic Data Commons https://gdc.cancer.gov/
Processed TCGA RNA-Seq 
data
Omicsoft http://www.omicsoft.com/oncoland-service/
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